We use cookies to customise content for your subscription and for analytics.
If you continue to browse Lexology, we will assume that you are happy to receive all our cookies. For further information please read our Cookie Policy.

Search results

Order by: most recent most popular relevance



Results: 1-10 of 45

Eli Lilly Canada Inc. v. Apotex Inc (2010 FCA 240)
  • Gowling Lafleur Henderson LLP
  • Canada
  • October 27 2010

This was an appeal of the decision of Madame Justice Gauthier (in the Federal Court) who had found that although Lilly met its burden to prove that Apotex infringed eight Lilly process patents related to the manufacture of the antibiotic cefaclor for material imported before June 3, 1998, Lilly failed to do so for the cefaclor imported into Canada after June 3, 1998


Purdue Pharma v Minister of Health, judicial review of decision of Office of Patented Medicines and Lliaison (“OPML”), TARGIN, July 8, 2010
  • Gowling Lafleur Henderson LLP
  • Canada
  • August 26 2010

Purdue filed a New Drug Submission ("NDS") as part of its application for a notice of compliance ("NOC") to market and sell the drug TARGIN in Canada


Astrazeneca v. Apotex, interlocutory motion to strike affidavit in PMNOC Regulations case
  • Gowling Lafleur Henderson LLP
  • Canada
  • May 21 2010

This was an appeal to the Federal Court of Appeal (FCA) of the decision of Justice Hughes refusing to strike an affidavit from the record


Time for change? Potential impact of Canada’s trade negotiations on pharma patents
  • Gowling Lafleur Henderson LLP
  • Canada
  • April 22 2013

Bringing a new drug to market is a costly and time-consuming endeavour. It is a process inherent with the risk of failure. In recognition of this


Methods of medical treatment claims issues in Canada, US and Europe
  • Gowling Lafleur Henderson LLP
  • Canada, European Union, USA
  • November 30 2012

In this presentation, Scott Foster and Konrad Sechley address methods of medical treatment claims issues in Canada, US and Europe


Apotex v Sanofi, case management directions on the late disclosure of documents or information
  • Gowling Lafleur Henderson LLP
  • Canada
  • May 21 2010

Prior to a case management conference within a streamlined case, the Prothonotary ordered the parties to make submissions at the conference on the question of whether a date should be set after which the parties required either consent of the other party or leave of the Court to serve a supplementary affidavit of documents or a corrected or completed information in answer to a discovery question


Pfizer v. Apotex, PMNOC Regulations decision
  • Gowling Lafleur Henderson LLP
  • Canada
  • May 21 2010

Apotex alleged in its NOA that Pfizer's patent was invalid for double patenting, anticipation, obviousness, lack of utility and over-breadth


Sanofi v ratiopharm, PMNOC Regulations decision irbesartan, March 5, 2010
  • Gowling Lafleur Henderson LLP
  • Canada
  • May 21 2010

Sanofi sought an order prohibiting the granting of a NOC to ratiopharm


AstraZeneca v. Novopharm, appeal of decision to strike Statement of Claim
  • Gowling Lafleur Henderson LLP
  • Canada
  • May 21 2010

This was an appeal to the Federal Court of Appeal (FCA) of the decision of Justice Hughes to strike AstraZeneca's Statement of Claim


Celgene Corporation v Canada (AG) - Supreme Court of Canada grants leave to appeal
  • Gowling Lafleur Henderson LLP
  • Canada
  • May 21 2010

The Supreme Court of Canada has granted Celgene Corporation's application for leave to appeal the decision of a majority of the Federal Court of Appeal regarding the jurisdiction of the Patented Medicine Prices Review Board